{"id":25918,"date":"2023-12-12T11:47:13","date_gmt":"2023-12-12T06:17:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25918"},"modified":"2024-09-17T17:03:03","modified_gmt":"2024-09-17T11:33:03","slug":"liso-cel-in-transcend-cll-004","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004","title":{"rendered":"Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>9th December 2023<\/td><\/tr>
Indications<\/td>Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)<\/td><\/tr>
Abstract Number<\/td>330<\/td><\/tr>
Abstract type<\/td>Oral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)<\/a><\/strong> after progression on a BTK inhibitor (BTKi) and BCL-2 inhibitor (BCL2i). The study included a broad population of patients with relapsed or refractory CLL or SLL with high unmet need who had received at least two prior lines of therapy, including a BTKi (n=118), to be treated with BREYANZI. According to the findings presented at the ASH 2023 conference, the sustained undetectable minimal residual disease (uMRD) rates with BREYANZI persisted in the long-term follow-up, showing an uMRD rate of 64% in blood and 60% in bone marrow. The overall response rate (ORR) increased to 44%, with a median duration of response (DOR) of 35.3 months. Notably, one patient initially responding partially achieved a complete response (CR) without additional therapy at 18 months. Among 9 patients with CR at the primary analysis, 8 maintained ongoing CRs, and one completed the study with the last assessment as a CR. Furthermore, the U.S. Food and Drug Administration (US FDA) is currently reviewing a supplemental Biologics License Application (BLA) for Breyanzi in the treatment of relapsed or refractory CLL, with results derived from the TRANSCEND CLL 004 study. The anticipated action date for this application is set for March 14, 2024.<\/strong><\/p>\n\n\n\n

Regarding safety, BREYANZI demonstrated a well-tolerated safety profile in the entire treated patient cohort (n=118). Notably, 85% of patients experienced any grade cytokine release syndrome (CRS), with 8% experiencing Grade 3 CRS and no occurrences of Grade 4\/5 CRS. Neurologic events (NEs) were reported in 45% of patients, including 18% with Grade 3 NEs, 1% with Grade 4 NEs, and no instances of Grade 5 NEs.<\/p>\n\n\n\n

KOL Insights<\/strong><\/h2>\n\n\n\n
\n

\u201cFor patients with relapsed or refractory CLL, current treatment options rarely provide complete responses, and durability of response is limited. With long-term follow-up from TRANSCEND CLL 004, the complete and lasting responses achieved with liso-cel are unprecedented in this patient population, with a deepening of responses observed over time and a manageable and predictable safety profile. Based on these results, liso-cel has the potential to be a significant advance in the treatment of relapsed or refractory CLL.\u201d\u2013Expert Opinion.<\/strong><\/p>\n<\/blockquote>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

With extended monitoring from TRANSCEND CLL 004, the sustained complete responses achieved with liso-cel set a new standard in this patient cohort, demonstrating deepening responses over time and maintaining a manageable and expected safety profile. These findings position liso-cel as a potentially groundbreaking advancement in the management of relapsed or refractory chronic lymphocytic leukemia (CLL).<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights<\/strong> – <\/p>\n\n\n\n

\n
\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Small Lymphocytic Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 9th December 2023 Indications Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) Abstract Number 330 Abstract type Oral TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) after progression on a BTK inhibitor […]<\/p>\n","protected":false},"author":6,"featured_media":25941,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,18917,21525,21534,21533,18442,11389,18919,21531],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-25918","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-chronic-lymphocytic-leukemia","tag-conference","tag-healthcare-conference","tag-hronic-lymphocytic-leukemia","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nLiso-cel in R\/R CLL\/SLL: Follow-up of TRANSCEND CLL 004<\/title>\n<meta name=\"description\" content=\"Findings from the TRANSCEND CLL 004 suggest that liso-cel could represent a noteworthy breakthrough in addressing relapsed or refractory CLL\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liso-cel in R\/R CLL\/SLL: Follow-up of TRANSCEND CLL 004\" \/>\n<meta property=\"og:description\" content=\"Findings from the TRANSCEND CLL 004 suggest that liso-cel could represent a noteworthy breakthrough in addressing relapsed or refractory CLL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-12T06:17:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:33:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12114235\/liso-cel-in-transcend-cll-004.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Liso-cel in R\/R CLL\/SLL: Follow-up of TRANSCEND CLL 004","description":"Findings from the TRANSCEND CLL 004 suggest that liso-cel could represent a noteworthy breakthrough in addressing relapsed or refractory CLL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004","og_locale":"en_US","og_type":"article","og_title":"Liso-cel in R\/R CLL\/SLL: Follow-up of TRANSCEND CLL 004","og_description":"Findings from the TRANSCEND CLL 004 suggest that liso-cel could represent a noteworthy breakthrough in addressing relapsed or refractory CLL","og_url":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-12T06:17:13+00:00","article_modified_time":"2024-09-17T11:33:03+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12114235\/liso-cel-in-transcend-cll-004.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004","url":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004","name":"Liso-cel in R\/R CLL\/SLL: Follow-up of TRANSCEND CLL 004","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12114235\/liso-cel-in-transcend-cll-004.png","datePublished":"2023-12-12T06:17:13+00:00","dateModified":"2024-09-17T11:33:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Findings from the TRANSCEND CLL 004 suggest that liso-cel could represent a noteworthy breakthrough in addressing relapsed or refractory CLL","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/liso-cel-in-transcend-cll-004#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12114235\/liso-cel-in-transcend-cll-004.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12114235\/liso-cel-in-transcend-cll-004.png","width":1200,"height":800},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12114235\/liso-cel-in-transcend-cll-004-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Chronic Lymphocytic Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Healthcare Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">hronic lymphocytic leukemia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Chronic Lymphocytic Leukemia<\/span>","<span class=\"advgb-post-tax-term\">Conference<\/span>","<span class=\"advgb-post-tax-term\">Healthcare Conference<\/span>","<span class=\"advgb-post-tax-term\">hronic lymphocytic leukemia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 12, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 12, 2023 11:47 am","modified":"Updated on Sep 17, 2024 5:03 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25918"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25918\/revisions"}],"predecessor-version":[{"id":29578,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25918\/revisions\/29578"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25941"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25918"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25918"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}